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Abstract
Background: HIV infected children are at increased risk of TB disease and require annual TB screening. Data on use
of IGRA for TB screening in them are limited. We retrospectively evaluated the usefulness of Quantiferon Gold-in-tube
test (QFT), an IGRA in screening for LTBI in relatively healthy, immunologically stable HIV infected children.
Methods: HIV infected children with no prior history of TB were screened for latent TB as part of routine care. They
underwent risk of TB assessment, TST and QFT. QFT was repeated twice or three times depending on the quantitative
values. Independent test validation was also performed.
Results: Eighty one children had 109 QFT tests. All had adequate mitogen responses. The initial QFT was positive in 15
(18.5%) children; quantitative IGRA responses were 0.35-1.0 IU/mL in 9 (60%), 1.0-10 IU/mL in5 (33.3%) and >10 IU/mL
in 1 (6.7%). None that tested positive had documented TB exposure or TB disease. Baseline characteristics in the QFT
positive and negative groups were similar. Repeat testing within 17 weeks demonstrated reversion to negative in 79%
of cases. Repeat blinded independent testing of all QFT positive results and a random selection of initial negative tests
demonstrated concordance in 96% of cases. Seven children (QFT > 1.0 IU/mL or positive TST) were offered INH
preventive therapy. In no case has TB disease developed in 2 years of close follow-up.
Conclusions: QFT is a valid method for LTBI screening relatively healthy, immunologically stable HIV infected children.
However, reversion to negative on repeat testing and lack of correlation with TST results and risk of TB exposure makes
interpretation difficult.
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Background
Tuberculosis is the leading cause of death in persons liv-
ing with HIV. It is estimated that one third of the 33.3
million people living with HIV worldwide are infected
with tuberculosis (TB). The annual risk of developing TB
disease in this context is between 7% and 10% [1]. More-
over, overall mortality is twofold higher for HIV/TB co-
infected individuals compared to those with isolated HIV
infection [2]. Consequently, diagnosis of latent TB infec-
tion (LTBI) and provision of chemotherapy to those test-
ing positive for LTBI is strongly recommended [3].
The tuberculin skin test (TST) has been used for de-
cades to diagnose LTBI [4]. For HIV infected children an
annual TST is recommended due to their high risk of pro-
gression to disease [3]. However, the utility of the TST is
limited due to suboptimal sensitivity and specificity [5].
False negative TST results are of particular concern [6].
Interferon gamma release assays (IGRAs) are now rec-
ommended as an alternative method of diagnosis of LTBI
in HIV infected persons [5]. IGRAs have performed well
in HIV infected adults without severe immune suppres-
sion, but less so in those with severe immune comprom-
ise, leading to large numbers of indeterminate response
[7,8]. However, there is a paucity of data on the utility of
IGRA in HIV infected children especially in low TB bur-
den setting. In high TB endemic setting, poor to moderate
agreement between TST and IGRAs have been reported in
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both HIV infected adults and children [9]. Recent data
from South Africa, a high TB burden country showed that
IGRAs were more likely to be positive in HIV uninfected
compared to HIV infected children [10]. In this report, we
present our experience on the use of the Quantiferon
Gold-in-tube test (QFT) in screening for LTBI in a rela-
tively healthy, immunologically stable, cohort of HIV in-
fected children in a low incidence setting.
Methods
We retrospectively reviewed the results of screening for
LTBI performed in our HIV clinic over a one year period
(2010–2011). During this period QFT had been used on
a trial basis concurrent with TST as a matter of routine.
All HIV-infected children less than 19 years of age at-
tending the pediatric HIV clinic at the Hospital for Sick
Children, Toronto, with no prior history of TB infection
or disease were screened for latent TB infection as part
of routine care. A detailed questionnaire was administered
to all children and/or their caregivers, as appropriate, to
assess their risk for exposure to TB. BCG vaccine status
was assessed by history and the presence of BCG scar. All
those who had a history of BCG vaccination or the pres-
ence of a BCG scar were considered to have had BCG
vaccine. A TB incidence of >25/100,000 population was
considered to be a TB endemic country. All children
underwent complete physical examination and blood
testing including viral load and CD4 count in accord-
ance with routine clinical care. All children underwent
TST and QFT testing on the same day. The study was
approved by the Research Ethics Board of the Hospital
for Sick Children.
Tuberculin skin testing was performed by the Mantoux
method using TUBERSOL® (Tuberculin Purified Protein
Derivative, Sanofi Pasteur). TST was considered positive if
the induration at its widest transverse diameter was
greater than or equal to 5 mm 48–72 hours after place-
ment in accordance with the Canadian Tuberculosis Stan-
dards [11]. The results of the first TST were read by a
physician or other appropriately trained health care pro-
fessional where possible and the rest were self read by the
child’s caregiver. The caregivers were provided with a tu-
berculin test record form that contains palpable examples
of 0 mm, 1–7 mm, 7–9 mm and ≥10 mm induration.
They were orally instructed to feel the child’s TST site be-
tween 48 and 72 hours after placement and to immedi-
ately see a physician if they noticed any swelling or
induration in order to confirm the induration and meas-
ure its size. For those whose initial TST was self-read and
had an initial positive QFT, the TST was repeated and
read by a physician or other appropriately trained health
care professional when they came for their routine clinical
follow up visit.
QFT assay was performed using the QuantiFERON®-TB
Gold In-Tube (Cellestis) test according to manufacturer
instructions [12]. Blood was drawn by the on-site pediatric
phlebotomy service. The tubes were shaken gently to coat
the sides of the tubes and transported to an on-site labora-
tory within 2 hours. The tubes were then incubated for
16–24 hours, centrifuged and the plasma was removed
and frozen. The QFT assay was done in batches of 26
samples. For each batch an 8 point standard curve was
obtained according to manufacturer’s instructions and
quality control criteria and using manufacturer supplied
reagents. Results were interpreted according to manu-
facturer’s guidelines: an IFN concentration of 0.35 IU/
ml over the nil concentration was classified as positive.
Nil concentrations of 8.0 IU/ml and mitogen differences
of 0.5 IU/ml were considered indeterminate. The labora-
tory performing the assay participates in an ongoing gen-
eral quality control program.
All children with an initial positive QFT or TST were
re-evaluated clinically and with chest radiography to look
for signs of active TB. The QFT was repeated in all such
children. For those who did not have a consistent QFT re-
sponse (TB antigen response corrected for Nil control) >
1.0 IU/mL in the second testing, QFT was repeated for
the third time. All initial and repeat positive QFT tests
(>0.35 IU/mL) as well as 8 randomly selected negative
tests were repeated in another laboratory with expertise in
performing the test in a blinded manner from the original
batched frozen samples to validate test results.
Results
Between July 2010 and June 2011, all 83 HIV infected
children attending the clinic were screened for latent
TB. Eighty one were included in our analysis; 2 children
previously treated for pulmonary TB were excluded. The
mean age of participants was 12.5 ± 4.3 years, 43(55%)
were female and 6 (7%) were less than 5 years of age.
None had a documented history of TB exposure. Ap-
proximately 30% of the children (Africa 19%, South and
Central America 5%, South and South East Asia 4%,
Russia 1%, Europe 1%) and 86% of their mothers (Africa
61%, South and Central America 1%South and South
East Asia 7%, Europe 17%) were born in countries en-
demic for TB, and 32% of the children had received BCG
vaccine prior to arrival in Canada. According to the revised
CDC HIV criteria, at the time of presentation, 9 subjects
(11%) were classified as having had severe symptoms
(class C), 21 subjects (26%) as having had moderate
symptoms (class B), 28 subjects (35%) as having had
mild symptoms (class A) and 23 subjects (28%) as hav-
ing had no symptoms (class N). With regards to the
CDC immunological categories, a history of severe im-
mune suppression, moderate immune suppression, and
no suppression was noted for 25(30%), 28 (35%) and
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28 (35%) subjects, respectively. Mean CD4 percent, and total
CD4 count at the time of QFT testing were 31.9% ± 9.6%,
and 827 ± 459 cells/mL, respectively. Sixty eight (82%) were
antiretroviral experienced, although only 64 subjects (79%)
were currently receiving combination ART.
Baseline demographic and HIV-related characteristics
are depicted in Table 1. There were no significant differ-
ences between groups with respect to age, sex, body mass
index, place of birth, place of mother’s birth, CDC clinical
or immunologic category, receipt of antiretroviral therapy,
CD4 percent, CD4 count, or viral load.
The details of QFT testing over time are provided in
Figure 1 and Table 2. In total, there were 109 tests per-
formed on 81 children. All had adequate mitogen responses
including 105 (96.3%) with values of > 10 IU/mL, the others
being 8.5 IU/mL, 8.03 IU/mL, 6.54 IU/mL and 3.28 IU/mL.
All 5 children whose CD4 count was less than 350 cells/μL
(lowest being 120 cells/μL) had robust mitogen re-
sponses >10 IU/mL. Eighty of 81 children had valid initial
QFT results; one had an indeterminate result due to high
IFN-gamma activity in the nil control tube (>10 IU/mL).
QFT testing was repeated twice on this patient, both with
valid results.
The initial QFT was positive in 15 children. Of these, 9
(60%) were low positive with TB antigen responses (cor-
rected for Nil control) between 0.35 IU/mL and 1.0 IU/
mL (Table 2). Of the remaining 6 children, 5(33.3%) had
TB antigen responses (corrected for Nil control) between
1.0 IU/mL and 10 IU/mL and 1 (6.7%%) had robust TB
antigen response (corrected for Nil control) >10 IU/mL.
There were no significant differences between the children
who had their first QFT IT positive or negative with re-
spect to age (p = 0.24), BMI (p = 0.38), country of birth
(p = 0.63), country of mother’s birth (p = 0.34), CD4 count
(p = 0.83) or viral load (p = 0.45). The two children ex-
cluded from this analysis because of prior treatment for TB
both had positive QFT results with responses >10 IU/ml.
The QFT was repeated in 14 of the 15 children with initial
positive results between 7 and 17 weeks (mean 12 weeks)
after the first QFT; one was not repeated because the child
had transitioned to adult care in the interim. None of the
children had a change in their immunologic status or anti-
retroviral therapy between tests. Eleven (79%) of the
14 second QFT tests reverted to negative including all
of those that had an initial low positive QFT of 1.0 IU/
mL or less. Of the 5 children whose initial QFT value
Table 1 Baseline characteristics
Characteristics QFT + (n = 15) QFT- (n = 65) P
Mean age 13.8(+/−3.5) 12.1+/−4.5 0.16
Age < 5 0 6(9%) 0.22
Females 5(33.3%) 38(57.5%) 0.09
Mean BMI 20.6+/−3.6 20.2+/−4.6 0.71
Born in TB endemic region 10(66.7%) 46(69.7%) 0.82
Mother born in TB endemic region 14(93.3%) 56(84.9%) 0.39
BCG vaccinated 6(40%) 20(30.3%) 0.47
Mean CD4% 31.4+/−11.3 32.1+/−9.3 0.79
CD4 > 25% 10(66.7%) 53(80.3%)
0.51CD4 15-25% 4(26.7%) 10(15.2%)
CD4 < 15% 1(6.7%) 3(4.6%)
Mean CD4 count 744+/−331.5 846.7+/−483.8 0.44
Median CD4 count (IQR) 769(481–1043) 731(525–1012) 0.88
Viral load log10 copies/ml 3.6+/−1.3 3.5+/−0.86 0.87
Undetectable viral load 10(66.7%) 39(59.1%) 0.59
No symptoms* 5(33.3%) 18(27.3%)
0.91
Mild symptoms* 5(33.3%0 23(34.8%)
Moderate symptoms* 4(26.7%) 17(25.8%)
Severe symptoms* 1(6.7%) 8(12.1%)
Proportion on ARV 13(86.7%) 55(83.3%) 0.75
Median duration of ARV in years (IQR) 7.33(2.2-10.84) 8.04(1.84-11.8) 0.91
3TC monotherapy 0 4(6.1%) 0.73
Combination ART 13(86.7) 51(77.3%) 0.42
*at initial presentation; BMI – Body Mass Index; CD 4 – Cluster of Differentiation 4; ARV – Anti Retroviral Therapy; 3TC –Lamivudine.
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was above 1.0 IU/mL, 3 remained positive, 2 reverted
to negative.
The 2 children who had repeated QFT values of greater
than 1.0 IU/mL were placed on treatment for LTBI. The
remaining 12 had a third QFT performed between 6 and
28 weeks (mean 14 weeks) after the second QFT assay. Of
these, 9 remained negative, 2 reverted to low positive and
one remained low positive (Table 2). The child whose
initial QFT was indeterminate had his QFT IT repeated
twice and both had valid results; the second QFT result
was negative (0.86 IU/mL with high background IFN
activity of 6.02 IU/mL in the nil tube), the third positive
(2.38 IU/mL).
Forty eight samples from the original batched samples
were retested in an alternate laboratory, of which 40
were initially positive and 8 were initially negative. Forty
six out of the 48 (96%) samples had consistent interpret-
ative results on retesting (Table 2). The repeat blinded
testing of the initially negative results were selected
using an online random number generator programme
(http://www.random.org/integers/) using the study num-
bers. If the particular study number had an initial positive
Figure 1 Flowchart of QFT testing.
Table 2 TB antigen response (corrected for Nil control) in those with positive first QFT result
QFT −1 (IU/mL) Repeat (IU/mL) QFT −2 (IU/mL) Repeat (IU/mL) QFT −3 (IU/mL) Repeat (IU/mL) TST (mm)
1 3.71 9.68 5.41 5.52 0
2 2.88 4.1 5.28 5.27 0
3 >10 >10 0.31 0.38 −0.02 0.01 0
4 2.23 1.98 −0.03 −0.01 0.02 0 0
5 1.64 1.19 0.08 −0.03 0.08 0.09 0
6 1.07 1.21 0.92 0.94 0.42 0.25 0
7 0.92 1.16 0.29 0.21 0.38 0.37 0
8 0.7 0.9 0.03 0.28 0.03 0.06 0
9 0.53 0.53 0.23 0.14 0.8 0.87 0
10 0.51 0.42 0.04 0 0.02 0.09 0
11 0.43 0.76 0.14 0.11 −0.04 0 0
12 0.42 0.46 0.06 0.02 0.03 0 0
13 0.39 0.59 0.07 0 0.01 0.01 13
14 0.36 0.36 0.04 −0.02 −0.01 0.01 0
15 0.45 Transitioned to adult care (no repeat testing) 0
Positive QFT result > 0.35 IU/mL.
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QFT result, that number was skipped. Eight such samples
were randomly selected. The 8 randomly selected negative
tests remained negative upon repeat testing in the second
laboratory with a mean difference of 0.036 IU/mL (range
0 – 0.15 IU/mL). Of the 2 discrepant results one went
from negative to positive (0.31 IU/mL to 0.38 IU/mL) and
one reverted to negative (0.42 IU/mL to 0.25 IU/mL).
Of the 81 included children, 65 (80.2%) had initial self-
read TST’s, the remainder being physician read. Of those
with positive QFT’s, 10 were self-read and 5 were physician
read. All children whose initial TST was self-read, had re-
peat physician read TST’s 97 to 350 days (mean 185 days)
after the self-read TST. None had known contact with TB
in the interval between tests. None of the TSTs done the
first time were positive. Only one of the repeat tests was
positive. In this child the physician read repeat TST dem-
onstrated 13 mm of induration. The patient’s initial QFT
was a low level positive (0.39 IU/mL) while 2 subsequent
QFT’s were negative. He was an 11 year old boy, born in
Burundi, who had moved to Canada 4.5 years prior to the
reactive TST. He had no known TB contacts, was clinically
well, and had a normal chest radiograph. He had received
BCG vaccine in early infancy.
All the children with positive first QFT were evaluated
clinically and radio graphically for signs of active TB and
none of them had any symptoms or signs of disease. All
children with TB antigen response (corrected for Nil
control) >1 IU/mL or a positive TST were offered INH
preventive therapy. Seven children received INH pre-
ventive therapy. In no case has TB disease developed in
2 years of close follow-up.
Discussion
Our results indicate that QFT testing of relatively healthy,
immunologically stable, HIV infected children produces
valid results in the majority of cases. This would indicate
that QFT can be used in this population. However, several
potential problems were observed. First, only one A child
with positive QFT results had positive TST result. Given
that these children were relatively healthy and immuno-
logically stable and had no history of TB exposure, one
would expect strong concordance with TST. Second, as
has been observed in other patient populations and in
healthcare workers, there were significant reversions par-
ticularly in those with low positive results (0.35-1.0 IU/mL
range) [13]. Thus, the reliability of the currently recom-
mended interpretive cut-off for a positive QFT test should
be questioned. Guidelines based on this cut off for HIV in-
fected children [5] may need to be revised to incorporate
quantitative IFN-gamma responses.
The unexpectedly high rate of positive QFT results was
a surprising observation. A detailed clinical assessment of
the children with positive results demonstrated that none
had documented exposure to tuberculosis or clinical or
radiographic evidence of TB disease, and none had react-
ive TSTs. Furthermore, repeat QFT testing within 17 weeks
of the first test demonstrated reversion to negative in 11
of 14 cases. A review of phlebotomy and laboratory proce-
dures found no issues related to sample collection, label-
ling or processing. Because of reports linking false positive
QFT results to specific lots [14], we reviewed all QFT tests
performed between September and November 2010, when
our study samples were tested. In one run there was a 50%
positive rate in 26 non-HIV infected patients, but these
were all close contacts with positive TSTs. Testing of other
patients through the laboratory also produced results that
correlated very well with gradient of exposure [15]. Finally,
the QFT results from 48 samples in our lab showed 96%
concordance with those obtained in a blinded fashion by
an independent laboratory. Taken together, these observa-
tions strongly suggest that test performance was excellent
and the results valid from a quality assurance perspective,
and raise serious doubts as to the currently-recommended
interpretive cut-off for a positive QFT test.
The rate of indeterminate results is an important meas-
ure of the usefulness of the QFT. The observation that only
0.9% of the 109 tests done in our study produced indeter-
minate results is reassuring in this regard. This finding cor-
roborates those of several other studies involving relatively
healthy HIV infected adults. The rate of indeterminate re-
sults ranged from 2–6% in studies of HIV infected adults
in high income countries [16-22]. By contrast, high
rates of indeterminate results (20% and 66%) have been
noted in children with immune compromising conditions
other than HIV [23,24] and in otherwise healthy children
less than 5 years of age [25]. In our study, the one child
with indeterminate result was 18 years old with a CD4
count of 585/μL and undetectable viral load.
Conversions and reversions have been observed with
serial QFT testing making interpretation of a single QFT
result difficult. In a study of healthy adults treated for
active tuberculosis, reversion to negativity was observed
in 32.1% of cases [9]. Among health care workers who
underwent weekly testing, 28.6% displayed conversions
and reversions, all with TB antigen responses (corrected
for Nil control) <3.0 IU/mL [26]. Pai et al. reported 24%
reversions on serial testing in health care workers with 78%
of them occurring with TB minus nil responses <1.0 IU/ml
[13]. Possible explanations for reversions include clearing
of TB infection, biological variation in interferon gamma
levels, or variability in laboratory and test procedures.
There may be a zone of uncertainty around the manufac-
turer’s cut off of 0.35 IU/mL where reversions and conver-
sions are more frequent [27].
In our study, serial testing was done only for those
who had an initial positive QFT. Hence our data reflect
more reversions than conversions upfront. Our rates of
inconsistent response for those with positive QFT was
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78.6% (11/14) among those tested on 2 occasions and
91.6% (11/12) for those tested 3 times. All 8 children
with TB antigen response (corrected for Nil control)
values of 0.35-1.0 IU/mL who had serial QFT testing
done, had inconsistent responses on serial testing. These
findings concur with those observed using the ELISpot
test in which almost 50% of HIV-infected children with
probable or definite TB disease demonstrated reversions
during treatment and another 50% converted from nega-
tive to positive during treatment [28].
Many guidelines have been developed incorporating
IGRAs in screening for LTBI. The latest United States
Centers for Disease Control (CDC) recommendations ad-
vocate for the use of either an IGRA or TST in screening
for LTBI, with a caveat that even multiple negative test re-
sults cannot fully exclude TB infection [5]. The latest
Canadian guidelines adopt a step wise approach for HIV
infected subjects whereby TST is recommended as an ini-
tial screen and the IGRA’s reserved as optional for those
whose TST was negative [29]. Neither guideline makes a
distinction between robust and borderline positive IGRA
results. Our data, as well as those of others [13,27], suggest
that some allowance should be provided in the interpret-
ation of low IFN-gamma responses (TB antigen response
corrected for Nil control values 0.35-1.0 IU/mL) where re-
versions are particularly common. While further study is
needed to fully understand the significance of these low
positive results, it is quite plausible that many of these
subjects do not have LTBI. If this could be confirmed by
further study, guidelines could be adjusted to recommend
repeat testing without immediate treatment for those with
borderline IGRA results in whom the risk of TB is deemed
to be low. Identification of a positive IGRA may have sig-
nificant implications for the patient, family and the facility.
Our experience illustrates the importance of repeating the
tests where the results seem anomalous.
Our study had several limitations in addition to its retro-
spective design. As is common to all studies pertaining to
the diagnosis of LTBI, the absence of a reliable gold stand-
ard is problematic. Thus, it is difficult to interpret the sig-
nificance of low positive reverting or converting QFT test
results without long term follow-up. A second limitation
was that the initial TST testing results were self-read.
However this reflects routine clinical practice in many set-
tings with low burden of TB. In addition, our routine was
to have the TST repeated and read by a physician or health
care worker if the initial QFT was potentially positive.
Third, because we restricted retesting to those whose initial
results were positive, we were unable to comment on con-
version rates. Fourth, the number of children screened was
relatively small, limiting the power of our observations.
In contrast to findings in adults with CD4 counts < 250
cells/μL [30], we do not think that HIV-related immune
suppression was a likely explanation for negative TST
or Quantiferon results in our cohort, because the vast
majority were healthy and had normal CD4 counts. A
relative strength was the validation of our IGRA results
by repeat testing in a separate laboratory blinded to our
results.
Conclusion
In conclusion, QFT exhibits a high level of test validity
in relatively healthy, immunologically stable HIV infected
children. However, many subjects exhibited low level posi-
tive test results (0.35 – 1.0 IU/mL), reversion to negative,
and lack of correlation with TST results, making interpret-
ation difficult. Future studies are needed to determine the
true significance of low positive IGRA results. We recom-
mend repeat testing of low level results, and determination
of cut off values at which results remain consistently posi-
tive or negative. Guidelines that incorporate QFT use in
HIV infected children may need to incorporate the utility
of quantitative IFN-gamma values in interpreting QFT
results and the need to repeat low positive results.
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